130 related articles for article (PubMed ID: 36469080)
1. Increased FDG Uptake in Skin Rashes Caused by EGFR Inhibitors.
Erol Fenercioğlu Ö; Cin M; Beyhan E; Şahin R; Çermik TF
Clin Nucl Med; 2023 Jan; 48(1):e46-e47. PubMed ID: 36469080
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
3. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
4. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer.
Choi YJ; Kim MJ; Lee BH; Kwon MJ; Hwang HS
Yonsei Med J; 2016 Jan; 57(1):232-7. PubMed ID: 26632406
[TBL] [Abstract][Full Text] [Related]
6. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
7. Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.
Lee J; Lee EJ; Moon SH; Kim S; Hyun SH; Cho YS; Choi JY; Kim BT; Lee KH
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1438-1447. PubMed ID: 28488029
[TBL] [Abstract][Full Text] [Related]
8. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
Gerber PA; Kukova G; Buhren BA; Homey B
Dermatology; 2011; 222(2):144-7. PubMed ID: 21346311
[TBL] [Abstract][Full Text] [Related]
9. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
10. Improving the assessment of erlotinib-induced rashes: a key to early detection and effective management.
Chon SY; Riddel C
J Support Oncol; 2009; 7(6):218-9. PubMed ID: 20380329
[No Abstract] [Full Text] [Related]
11. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
12. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
13. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
14. Association Between 18F-Fluorodeoxyglucose Uptake and Mutation Status of Epidermal Growth Factor Receptor in Sinonasal Tract Cancer.
Suzuki H; Sasaki E; Tamaki T; Kodaira T; Nishio M; Nishikawa D; Beppu S; Terada H; Sawabe M; Hanai N
Anticancer Res; 2023 Jul; 43(7):3247-3253. PubMed ID: 37351957
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Scheffler M; Zander T; Nogova L; Kobe C; Kahraman D; Dietlein M; Papachristou I; Heukamp L; Büttner R; Boellaard R; Lammertsma AA; Querings S; Stoelben E; Engel-Riedel W; Neumaier B; Wolf J
PLoS One; 2013; 8(1):e53081. PubMed ID: 23308140
[TBL] [Abstract][Full Text] [Related]
16. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW; Pang JS; Ko YS; Chang CJ; Wang CW; Chen WT; Chen CB; Hui RC; Hung SI; Lu LY; Lu KL; Wang CL; Wu CE; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Chen MJ; Chung WH
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):328-339. PubMed ID: 36366861
[TBL] [Abstract][Full Text] [Related]
17. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
Liu HB; Wu Y; Lv TF; Yao YW; Xiao YY; Yuan DM; Song Y
PLoS One; 2013; 8(1):e55128. PubMed ID: 23383079
[TBL] [Abstract][Full Text] [Related]
18. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
19. Rash from EGFR inhibitors: opportunities and challenges for palliation.
Solomon BM; Jatoi A
Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
